CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease.

Hanna R, Frangoul H, Pineiro L, McKinney C, Mapara M, Dalal J, Rangarajan HG, Atkins H, Sharma A, Chang KH, Jaskolka MC, Kim K, Yu Q, Mei B, Afonja O, Walters MC, RUBY Investigators

Open source

DOI: 10.1056/nejmoa2415550
Published: 2026 Apr 2
Container: The New England journal of medicine
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa2415550,
  title = {CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease.},
  author = {Hanna R and Frangoul H and Pineiro L and McKinney C and Mapara M and Dalal J and Rangarajan HG and Atkins H and Sharma A and Chang KH and Jaskolka MC and Kim K and Yu Q and Mei B and Afonja O and Walters MC and RUBY Investigators},
  year = {2026},
  journal = {The New England journal of medicine},
  doi = {10.1056/nejmoa2415550},
  url = {https://doi.org/10.1056/nejmoa2415550}
}

RIS

TY  - JOUR
TI  - CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease.
AU  - Hanna R
AU  - Frangoul H
AU  - Pineiro L
AU  - McKinney C
AU  - Mapara M
AU  - Dalal J
AU  - Rangarajan HG
AU  - Atkins H
AU  - Sharma A
AU  - Chang KH
AU  - Jaskolka MC
AU  - Kim K
AU  - Yu Q
AU  - Mei B
AU  - Afonja O
AU  - Walters MC
AU  - RUBY Investigators
PY  - 2026
JO  - The New England journal of medicine
DO  - 10.1056/nejmoa2415550
UR  - https://doi.org/10.1056/nejmoa2415550
ER  -

APA

R, H., H, F., L, P., C, M., M, M., J, D., HG, R., H, A., A, S., KH, C., MC, J., K, K., Q, Y., B, M., O, A., MC, W., & Investigators, R. (2026). CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease.. The New England journal of medicine. https://doi.org/10.1056/nejmoa2415550

Source records

pubmed · retrieved 2026-09-26T21:11:45.319Z